Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,575,987

« Back to Dashboard

Claims for Patent: 5,575,987

Title: Method of producing sustained-release microcapsules
Abstract:A method of producing sustained-release microcapsules containing a biologically active substance from an W/O emulsion comprising an inner aqueous phase containing said biologically active substance and an external oil phase containing a biodegradable polymer, characterized in that microcapsules formed on microencapsulation of said biologically active substance with said biodegradable polymer are heated at a temperature not lower than the glass transition temperature of said biodegradable polymer but not so high as to cause aggregation of the microcapsules. This method enables the production of very useful sustained release microcapsules adapted to release a bologically active substance at a calculated rate over a protracted time period starting immediately following administration without an initial burst within one day following administration.
Inventor(s): Kamei; Shigeru (Takarazuka, JP), Yamada; Minoru (Kawanishi, JP), Ogawa; Yasuaki (Ohyamazaki-cho, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:08/562,634
Patent Claims: 1. A sustained release form of (Pyr)-Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C.sub.2 H.sub.5 in the form of a plurality of microcapsules of (Pyr)-Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C.sub.2 H.sub.5 free from aggregation, said microcapsules containing (Pyr)-Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C.sub.2 H.sub.5 from a W/O emulslon comprising an inner aqueous phase containing said (Pyr)-Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C.sub.2 H.sub.5 and an external oil phase containing an aliphatic biodegradable polymer based upon an aliphatic ester has an average molecular weight of about 3,000 to 30,000 and a dispersity of about 1.2 to 4.0 and the content of the biodegradable polymer is 90.9% (w/w) to the microcapsules, wherein said microcapsules formed on microencapsulation of said (Pyr)-Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C.sub.2 H.sub.5 with said biodegradable polymer are then heated at a temperature at or above the glass transition temperature of said aliphatic biodegradable polymer, said heating being conducted at a temperature that does not cause aggregation of the microcapsules.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.